Autor
Mostrando ítems 1-3 de 3
-
A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome
Caronia, Daniela; Martín, Miguel; Sastre, Javier; de la Torre Montero, Julio César; García-Saénz, Jose Angel; Alonso, Maria Rosario; Moreno, Leticia; Pita, Guillermo; Diaz-Rubio, Eduardo; Benítez, Javier; González-Neira, Anna (01/04/2011). -
Regulatory CDH4 genetic variants associate with risk to develop capecitabine-induced hand-foot syndrome
Ruiz Pinto, Sara; Pita, Guillermo; Martín, Miguel; Núñez Torres, Rocío; Cuadrado, Ana; Shahbazi, Marta; Caronia, Daniela; Kojic, Alexander; Moreno, Leticia; de la Torre Montero, Julio César; Lozano, María; López-Fernández, Luis Andrés; Ribelles, Nuria; García-Saénz, Jose Angel; Alba, Emilio; Milne, Roger; Losada, Ana; Pérez-Moreno, Mirna; Benítez, Javier; González-Neira, Anna (20/01/2021). -
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis
Martín, Miguel; Martínez, Noelia; Ramos, Manuel; Calvo, Lourdes; Lluch, Ana; Zamora, Pilar; Muñoz, Montserrat; Carrasco, Eva; Caballero, Rosalía; García-Saénz, Jose Angel; Guerra, Eva; Caronia, Daniela; Casado, Antonio; Ruiz-Borrego, Manuel; Hernando, Blanca; Chacón, Jose Ignacio; de la Torre Montero, Julio César; Jimeno, Maria Angeles; Heras, Lucía; Alonso, Rosario (19/01/2015).